title: Synbiotics decrease the incidence of septic complications in patients with severe SIRS: a preliminary report.
abstract: The purpose of this study was to evaluate if synbiotic therapy can correct the deteriorated gut flora and environment in patients with severe systemic inflammatory response syndrome (SIRS). Twenty-nine SIRS patients, who fulfilled a serum C-reactive protein (CRP) level >10 mg/dl, received synbiotics (Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides) (S group) and were compared with previous observations in 26 patients without synbiotics (NS group). Analysis of fecal flora confirmed that patients in the S group had significantly greater levels of beneficial Bifidobacterium, Lactobacillus, and total organic acids (particularly short-chain fatty acids) than those in the NS group. The incidence of infectious complications such as enteritis, pneumonia, and bacteremia was significantly lower in the S group than in the NS group. Synbiotics maintain the gut flora and environment and decrease the incidence of septic complications in patients with severe SIRS. Further randomized controlled study is necessary to determine the effects of synbiotics.
authors: Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Suita City, Osaka 565-0871, Japan. shimiken@hp-emerg.med.osaka-u.ac.jp
authors: Kentaro
authors: K
authors: Shimizu
authors: Hiroshi
authors: H
authors: Ogura
authors: Miki
authors: M
authors: Goto
authors: Takashi
authors: T
authors: Asahara
authors: Koji
authors: K
authors: Nomoto
authors: Masami
authors: M
authors: Morotomi
authors: Asako
authors: A
authors: Matsushima
authors: Osamu
authors: O
authors: Tasaki
authors: Kieko
authors: K
authors: Fujita
authors: Hideo
authors: H
authors: Hosotsubo
authors: Yasuyuki
authors: Y
authors: Kuwagata
authors: Hiroshi
authors: H
authors: Tanaka
authors: Takeshi
authors: T
authors: Shimazu
authors: Hisashi
authors: H
authors: Sugimoto
mesh_terms: D000328:Adult; D000368:Aged; D001644:Bifidobacterium / Q000254:growth & development*; D002097:C-Reactive Protein / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D005243:Feces / Q000737:chemistry / Q000382:microbiology; D005260:Female; D006801:Humans; D015994:Incidence; D007422:Intestines / Q000382:microbiology*; D007780:Lacticaseibacillus casei / Q000254:growth & development*; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000627:therapeutic use*; D010865:Pilot Projects; D019936:Probiotics / Q000627:therapeutic use*; D018805:Sepsis / Q000209:etiology / Q000517:prevention & control*; D012720:Severity of Illness Index; D018746:Systemic Inflammatory Response Syndrome / Q000150:complications / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D005227:Fatty Acids; D009844:Oligosaccharides; D002097:C-Reactive Protein